Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03829540 · ClinicalTrials.gov registry record · Phase 1

CD4CAR for CD4+ Leukemia and Lymphoma

A Phase 1 study of T-Cell Lymphoma and T-cell Leukemia, sponsored by Huda Salman.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
6
Study locations

NCT03829540: Recruiting Phase 1 study of T-Cell Lymphoma and T-cell Leukemia, sponsored by Huda Salman.

NCT03829540 is a Phase 1 study of T-Cell Lymphoma and T-cell Leukemia that is actively recruiting participants, run by Huda Salman. The registered enrollment target is 20 participants, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03829540, a Phase 1 study of T-Cell Lymphoma and T-cell Leukemia, is actively recruiting participants, sponsored by Huda Salman.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
6
Study locations

Study Summary

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD

Primary Outcome

To assess the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD4 lentiviral vector (referred to as "CD4CAR" cells) according to CTCAE grading. The feasibility of treating those adverse events and their duration till resolution will also be described.

Interventions

  • BIOLOGICAL CD4CAR

Study Locations (6)

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
  • Riley Hospital for Children - Indianapolis

New York

  • Albert Einstein Health Network - New York
  • Stony Brook Cancer Center - Stony Brook

Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-07-09
Est. Completion 2041-12
Phase Phase 1
Huda Salman

3 total trials

What NCT03829540 shows while recruiting

NCT03829540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD4CAR is the first listed.

NCT03829540 lists 6 locations in 4 states (Indiana, New York, Florida).

Frequently Asked Questions

What is clinical trial NCT03829540 about?

NCT03829540 is a clinical study titled "CD4CAR for CD4+ Leukemia and Lymphoma". This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-c...

What is the current status of trial NCT03829540?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-07-09. Estimated completion is 2041-12.

What conditions does trial NCT03829540 study?

This clinical trial studies the following conditions: T-Cell Lymphoma, T-cell Leukemia.

What interventions are being tested in trial NCT03829540?

The interventions under investigation include: CD4CAR (BIOLOGICAL).

Who is sponsoring clinical trial NCT03829540?

This trial is sponsored by Huda Salman, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03829540 being conducted?

This trial has 6 study locations across Florida, Indiana, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for T-Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03829540's enrollment target sits among peer trials

20 13th of 15 higher than 2 of 15 other T-Cell Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03829540, the US trial registry maintained by the National Library of Medicine. NCT03829540 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.